Sangamo BioSciences | SGMO - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Alaunos Therapeutics USD -1.19M 148K 2025-09
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
Amgen USD 3.83B 130M 2026-03
Bayer EUR 1.11B 1.65B 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 514.3M 128.8M 2026-03
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
Cipla INR 9.77B 6.21B 2025-12
Clal Biotechnology ILS -1.74M 7.46M 2022-12
Compugen USD 56.04M 63.93M 2025-12
CSL USD 2.64B 1.97B 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
Grifols EUR 320.55M 91.01M 2025-12
Ionis Pharmaceuticals USD -118M 97M 2026-03
J&J USD 6.62B 1.03B 2026-03
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Merck USD -1.88B 8.12B 2026-03
Novartis USD 4.24B 171M 2026-03
Omeros USD -35.41M 23.75M 2024-09
Pfizer USD 4.99B 340M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.94B 239M 2026-03
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03